CPhI is an established pharmaceutical event with over 30 years' experience of bringing together the movers and shakers in pharma. Uniting niche and top buyers and sellers together under one roof in nine event locations around the world, CPhI hosts quality conferences, free seminars, Awards and even pharma community charity expeditions.
For 30 years, FIME has brought together manufacturers spearheading innovation in medical devices and equipment and the distributors and buyers looking to help expand into new verticals and markets. FIME is the annual must-attend event for everyone in the healthcare industry in the Americas.
The MEDICA is the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals. The fair takes place once a year in Dusseldorf and is open to trade visitors only. Rising life expectancy, medical progress and the growing awareness of the people for their health are helping to increase the demand for modern treatment methods. This is where the Medica grabs and provides the medical device industry a central market for innovative products and systems that result in an important contribution to the efficiency and quality of patient care. The exhibition is divided into the areas of electromedicine and medical technology, information and communication technology, physiotherapy and orthopedic technology, disposables, commodities and consumer goods, laboratory equipment and diagnostic products. In addition to the trade fair the Medica conferences and forums belong to the firm offer of this fair, which are complemented by numerous activities and interesting special shows. The Medica is held in conjunction with the world's largest supplier fair for medicine, Compamed. Thus, the entire process chain of medical products and technologies are presented to the visitors and necessitates a visit to the two exhibitions for each industry expert.
Vitamins are trace organic substances that humans and animals must obtain from food to maintain normal physiological functions. They play an important role in human growth, metabolism, and development.
Bayer’s first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) Kerendia has received approval in the US to slow chronic kidney disease (CKD) progression in patients with type 2 diabetes (T2D). The US Food and Drug Administration (FDA) has cleared Kerendia (finerenone) to reduce the risk of sustained eGFR decline, kidney failure, cardiovascular death, non-fatal myocardial infarction (MI) and hospitalisation for heart failure in adult patients with CKD associated with T2D. The approval is based on data from the Phase III FIDELIO-DKD renal outcomes study, which showed Kerendia significantly reduced the combined primary endpoint of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care. The drug also lowered the risk of a composite of time to first occurrence of CV death, non-fatal myocardial infarction, non-fatal stroke or heart failure hospitalisation, thereby by also meeting secondary targets. “Kerendia is the first and only nonsteroidal mineralocorticoid receptor ...
A new test based on gene targeting technology CRISPR could diagnose Covid-19 infections in 45 minutes. It was recently outlined in a paper in the journal Nature Biotechnology.
Rheumatoid arthritis (RA) is an autoimmune disease with complex pathogenesis and an extremely high morbidity rate, which seriously affects the quality of the life of patients and brings economic burden to society. Thus, effective treatments of RA has become a global concern of the pharmaceutical industry.
Pfizer’s JAK inhibitor Xeljanz reduced the risk of severe outcomes in hospitalised adult patients with COVID-19 pneumonia who were not on ventilation, according to new study data. The STOP-COVID trial was conduction by Pfizer and the ARO from the Hospital Israelita Albert Einstein in Sao Paolo, Brazil, which was also the trial coordinating centre. Patients were randomised to receive either Xeljanz (tofacitinib) 10mg twice daily plus standard of care (SoC) or placebo twice daily plus SoC for up to 14 days or until hospital discharge. The trial demonstrated a reduced cumulative incidence of death or respiratory failure through day 28 with Xeljanz (18.1%) compared to placebo (29.9%). In addition, death from any cause occurred in 2.8% of Xeljanz-treated patients compared to 5.5% in the placebo group. In the study, serious adverse groups occurred in 14.1% of patients in the Xeljanz group and 12% in the placebo group. Protocol-specified adverse events ...
Diabetes is one of the most common chronic diseases and is mainly classified into type 1 diabetes, type 2 diabetes, gestational diabetes and others. Worldwide, 90% of diabetic patients suffer from type 2 diabetes, which greatly promotes the development of the diabetes drug market.
Research by the World Health Organization has shown that“Physically, it is much more difficult to stop the production of millions of sperm per day for men than to prevent women from releasing an egg every month.” In the contraceptive drugs market, contraceptive drugs for women account for 90%, and is gradually becoming just as accepted in China as it is in most other parts of the world.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.